FRANKLIN LAKES, N.J., March 13 /PRNewswire-FirstCall/ -- Medco Health Solutions, Inc. (NYSE: MHS) announced today that it has agreed to sell $300 million aggregate principal amount of 6-1/8 percent senior notes due March 15, 2013 and $1.2 billion aggregate principal amount of 7-1/8 percent senior notes due March 15, 2018 in an underwritten public offering. Citi, J.P. Morgan Securities Inc., Banc of America Securities LLC and Barclays Capital Inc. are acting as representatives of the several underwriters.
Medco intends to use the net proceeds from the offering to repay
borrowings under its senior unsecured revolving credit facility used to
fund the acquisition of PolyMedica Corporation in October 2007. The
offering is expected to close on March 18, 2008. The prospectus supplement
and accompanying prospectus related to the offering of the notes may be
obtained by contacting:
Citigroup Global Markets Inc.
Brooklyn Army Terminal,
140 58th Street, 8th Floor,
Brooklyn, NY 11220
Tel: (877) 858 5407
J.P. Morgan Securities Inc.
270 Park Avenue, 8th Floor,
New York, New York, 10017
Tel: (212) 834-4533
Banc of America Securities LLC
Capital Markets Operations
100 West 33rd Street, 3rd Floor
New York, NY 10001
Tel: (800) 294-1322
Barclays Capital Inc.
200 Park Avenue
New York, NY 10166
Attention: Fixed Income Syndicate
Tel: (888) 227-2275
Electronic copies of the prospectus supplement and accompanying prospectus are also available on the Securities and Exchange Commission Web site at http://www.sec.gov.
This press release does not constitute an offer to sell or the solicitation of an offer to buy any of the securities nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.
Medco Health Solutions, Inc. (NYSE: MHS) is the nation's leading pharmacy benefit manager based on its 2007 total net revenues of more than $44 billion. Medco's prescription drug benefit programs, covering one in five Americans, are designed to drive down the cost of pharmacy health care for private and public employers, health plans, labor unions and government agencies of all sizes, and for individuals served by the Medicare Part D Prescription Drug Program. Medco, the world's most advanced pharmacy(TM), is positioned to serve the unique needs of patients with chronic and complex conditions through its Medco Therapeutic Resource Centers; its diabetes pharmacy care practice, Liberty Medical; and its specialty pharmacy operation, Accredo Health Group, Inc. Medco is the highest-ranked independent pharmacy benefit manager on the 2007 Fortune 500 list. On the Net: http://www.medco.com.
This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that may cause results to differ materially from those set forth in the statements. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. We undertake no obligation to publicly update any forward- looking statement, whether as a result of new information, future events or otherwise. Forward-looking statements are not historical facts, but rather are based on current expectations, estimates, assumptions and projections about the business and future financial results of the pharmacy benefit management ("PBM") and specialty pharmacy industries, and other legal, regulatory and economic developments. We use words such as "anticipates," "believes," "plans," "expects," "projects," "future," "intends," "may," "will," "should," "could," "estimates," "predicts," "potential," "continue," "guidance" and similar expressions to identify these forward-looking statements. Medco's actual results could differ materially from the results contemplated by these forward-looking statements due to a number of factors.
|SOURCE Medco Health Solutions, Inc.|
Copyright©2008 PR Newswire.
All rights reserved